Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Privium Fund Management B.V.

Privium Fund Management B.V. lowered its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 31.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 233,037 shares of the biopharmaceutical company’s stock after selling 105,763 shares during the period. Ultragenyx Pharmaceutical comprises 0.7% of Privium Fund Management B.V.’s holdings, making the stock its 28th largest position. Privium Fund Management B.V. owned 0.24% of Ultragenyx Pharmaceutical worth $3,503,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Versant Capital Management Inc grew its stake in Ultragenyx Pharmaceutical by 662.9% in the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,001 shares during the period. Quantbot Technologies LP bought a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth about $48,000. Harbor Investment Advisory LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth about $52,000. Parallel Advisors LLC raised its position in shares of Ultragenyx Pharmaceutical by 778.4% during the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,440 shares during the period. Finally, Freestone Grove Partners LP bought a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at about $62,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Jefferies Financial Group decreased their price objective on Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, September 3rd. Barclays dropped their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $32.00 and set an “overweight” rating on the stock in a report on Thursday. Morgan Stanley lifted their price target on shares of Ultragenyx Pharmaceutical from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Wednesday. Citigroup reduced their price target on shares of Ultragenyx Pharmaceutical from $32.00 to $22.00 and set a “buy” rating for the company in a report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $29.79.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,066 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the sale, the chief financial officer owned 89,229 shares in the company, valued at approximately $1,362,526.83. This represents a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 8,510 shares of company stock worth $127,561 in the last 90 days. Corporate insiders own 5.20% of the company’s stock.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The UK medicines regulator has accepted Ultragenyx’s marketing application for rebi-vec (UX111), its gene therapy for Sanfilippo syndrome Type A, and is reviewing it. This is a step toward a possible UK authorization, but the therapy remains investigational and has not been approved. Company announcement
• Positive Sentiment: H.C. Wainwright and TD Cowen both reiterated Buy ratings, signaling that these analysts see potential despite recent price-target reductions. H.C. Wainwright rating TD Cowen rating
• Negative Sentiment: Several firms have lowered their price targets, reflecting more restrained expectations. Canaccord cut its target from $39 to $34, Citi reduced its target from $32 to $22, and Barclays lowered its target from $35 to $32; all retained Buy or Overweight ratings. The revisions may weigh on sentiment even as analysts remain positive on the shares. Canaccord target revision Citi target revision

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock traded down $0.14 during mid-day trading on Friday, reaching $15.43. The company’s stock had a trading volume of 4,049,110 shares, compared to its average volume of 3,379,657. Ultragenyx Pharmaceutical Inc. has a 12 month low of $12.73 and a 12 month high of $39.89. The business’s 50 day simple moving average is $16.02 and its 200 day simple moving average is $22.71. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -2.97 and a beta of 0.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The firm had revenue of $173.00 million for the quarter, compared to the consensus estimate of $182.49 million. Ultragenyx Pharmaceutical’s revenue was up 8.2% on a year-over-year basis. During the same period last year, the company posted ($1.81) EPS. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -3.45 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.